{
  "docId": "019de074-d961-7389-a20b-cd17e719b042",
  "docSlug": "eb72a4aa6f7d8bed68bc577a406605bf",
  "documentTitle": "BioAtla | Investor Presentation Deck | 44 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 44,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The chart displays 'Maximum % Change from Baseline in Sum of Target Lesions'.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d961-7389-a20b-cd17e719b042/27",
  "deckHref": "/decks/019de074-d961-7389-a20b-cd17e719b042",
  "deckJsonHref": "/decks/019de074-d961-7389-a20b-cd17e719b042.json",
  "deckAnchorHref": "/decks/019de074-d961-7389-a20b-cd17e719b042#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.74,
        "y": 0.39
      },
      "kind": "callout",
      "text": "Two out of three ROR2+ patients had a partial response following ozuriftamab vedotin treatment",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93043ba1-c5bd-41fb-aacc-4235b94966c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.58,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Waterfall chart showing patient response at variable dosing",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5977848-3174-4412-b89a-0afc9542d64d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.15,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Note: Not Evaluable (Strong, extensive fibroblastic stromal positivity reported)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08829f93-f168-48e5-b4b4-0db941fd89a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.63,
        "x": 0.034,
        "y": 0.088
      },
      "kind": "title",
      "text": "Encouraging Phase 1 results with BA3021 (Ozuriftamab Vedotin) in refractory patients with NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ea23373-94de-45ed-a792-d87040f28f2c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "77cd9e4b-ee3e-4c63-81ea-1c9519e91e32",
      "evidence": "chart/waterfall: Waterfall chart showing patient response at variable dosing",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}